

AD _____

Award Number: DAMD17-02-1-0256

TITLE: Novel Coactivators for Androgen Receptor

PRINCIPAL INVESTIGATOR: Donald B. DeFranco, Ph.D.

CONTRACTING ORGANIZATION: University of Pittsburgh
Pittsburgh, Pennsylvania 15260

REPORT DATE: April 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030731 149

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE April 2003		3. REPORT TYPE AND DATES COVERED Annual (15 Mar 02 - 14 Mar 03)
4. TITLE AND SUBTITLE Novel Coactivators for Androgen Receptor			5. FUNDING NUMBERS DAMD17-02-1-0256	
6. AUTHOR(S): Donald B. DeFranco, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pittsburgh Pittsburgh, Pennsylvania 15260 E-Mail: dod1@pitt.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) The point of contact between the extracellular matrix (ECM) and specific cell surface proteins (i.e. integrins) occurs at specialized structures termed focal adhesions, which include several signal transduction molecules such as focal adhesion kinase (FAK). Intracellular signaling pathways that are responsive to ECM attachment influence cell proliferation and are altered in cancer cells. For example, FAK is overexpressed in invasive and metastatic human tumors. Furthermore, FAK is elevated in metastatic prostate cancers and preferentially associated with tyrosine-phosphorylated paxillin, a direct target of FAK. We have found that in addition to its localization to focal adhesions, paxillin is also present within nuclei and can target to the nuclear matrix of CV-1 cells, cultured prostate cancer cell lines and human prostate tissue. Furthermore, paxillin functions as a coactivator for androgen receptor and glucocorticoid receptor, but not estrogen receptor and was found to directly interact with the androgen receptor via its carboxyl-terminal LIM domain. Thus, paxillin, a protein that responds to the metastatic state of prostate cancer cells, can directly influence androgen receptor transactivation. Future studies will be directed towards the assessment of ECM effects on this novel nuclear function of paxillin as it relates to androgen action				
14. SUBJECT TERMS: androgen receptor, paxillin, prostate cancer			15. NUMBER OF PAGES 12	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover _____	1
SF298 _____	2
Table of Contents _____	3
Introduction _____	4
Body _____	4-7
Key Research Accomplishments _____	8
Reportable Outcomes _____	8
Conclusions _____	8-9
References _____	9-12
Appendices _____	

Introduction

Androgens are required for the growth and development of the normal prostate gland (1) but also participate in the progression of prostate cancer, particularly in early stages (2). The principal mediator of androgen action within cells is the androgen receptor (AR), a member of a large super-family of nuclear receptors (3,4). Physiological effects of androgens result primarily from transcriptional regulation of specific target genes brought about by AR interaction with specific DNA sequences, or receptor associations with other transcription factors (5-7) or coactivators (8).

The AR has proven to be a particularly useful reagent for the identification of novel transcriptional coactivators (9-12). For example, Hic-5/ARA55 was first identified as a coactivator for AR (13) and later shown to potentiate the transactivation activities of a subset of steroid hormone receptors (14) including the glucocorticoid receptor (GR). While Hic-5/ARA55 was shown to associate with the nuclear matrix (14), most studies of this protein have focused on its focal adhesion binding (15,16). Hic-5/ARA55 is a member of the paxillin family of focal adhesion proteins (17,18) that share a closely related C-terminal LIM domain region (19). In addition to their localization within focal adhesions, members of the group 3 LIM domain family are also associated with the nucleus (16,20). In spite of the prevalence of nuclear group 3 LIM domain proteins, the physiologically relevant transcriptional targets regulated by these proteins remain largely undefined.

Body

A major focus of experiments outlined in Specific Aim 1 (i.e. Task 1) was to establish whether paxillin is a coactivator for AR in prostate cancer cell lines. We have found that the transactivation activity of AR on the androgen-responsive mouse mammary tumor virus (MMTV) promoter is potentiated in transiently transfected CV-1 monkey kidney fibroblast cells (Fig. 1) and PC-3 prostate cancer cells (Fig. 2).




Fig. 1: Paxillin enhances AR and GR but not ER transactivation in CV-1 cells. CV-1 cells were transiently transfected with varying amounts of a paxillin expression vector along with the appropriate luciferase reporter plasmid and AR (A), GR (B) or ER (C) expression vectors. Cells incubated in the presence or absence of 10^{-7} M dihydroxytestosterone (DHT) (A), 10^{-6} M dexamethasone (Dex) (B), or 10^{-8} M 17β -estradiol (E2) (C) for 24 h. Each point and error bar shows the mean \pm SD (N=4) normalized to total protein levels in each sample.

The coactivator activity of paxillin was also exerted on transiently transfected glucocorticoid receptor (GR) but not on estrogen receptor alpha (ER α) (Fig. 1). This selectivity of paxillin effects is analogous to that observed with Hic-5/ARA55, which was found to act as a coactivator for GR and AR but not ER (14).




Fig. 2. Paxillin enhances AR and GR transactivation in the PC-3 prostate cancer cell line. PC-3 cells were transiently transfected with indicated amounts of a paxillin expression vector along with a promoter-linked luciferase reporter plasmid and an AR (A) expression vector or empty expression plasmid (B). A GR-expressing vector was not necessary for the GR transactivation assay since PC-3 cells express functional GR. Cells were incubated in the presence or absence of 10^{-7} M DHT (A) or 10^{-6} M Dex (B) for 24 h. Histogram shows the mean \pm SD (N=4) relative luciferase activity normalized to total protein levels in each sample.

In order to identify the domain responsible for steroid receptor coactivator activity as outlined in Specific Aim1 (Task 1), paxillin amino- and carboxyl-terminal domains were transfected with AR into CV-1 cells. Results from these experiments showed that the C-terminal LIM domain of paxillin was as effective as full-length paxillin in potentiating the transactivation activity of AR and GR in CV-1 cells (Fig. 3). Basal activity of the MMTV promoter was not affected by carboxyl-terminal paxillin. In contrast to the effect of the carboxyl-terminal region of paxillin, overexpression of the amino-terminal region of paxillin did not potentiate AR transactivation in CV-1 cells (Fig. 3). However, the amino-terminal domain of paxillin was not neutral as its overexpression interfered with the coactivator activity of transfected full-length paxillin on AR and GR (Fig. 3). This “dominant negative” effect of the amino terminal region of paxillin did not result from reduced expression of transfected full-length paxillin (data not shown). Since AR and GR transactivation activity was not reduced by amino-terminal paxillin beyond that observed in the absence of overexpressed paxillin this domain of paxillin may not affect the functioning of other coactivators, at least at the levels expressed under these transfection conditions.




Fig. 3. Effect of paxillin C-terminus or N-terminus on AR or GR transactivation. CV-1 cells were transiently transfected with indicated amounts indicated of full-length (FL) paxillin, N-terminal (NT) paxillin, or C-terminal (CT) paxillin expression plasmids along with a promoter-linked luciferase reporter plasmid and AR (A,C) or GR expression plasmid (B,D) expression plasmids. Cells were incubated in the presence or absence of 10^{-7} M DHT (A,C) or 10^{-6} M Dex (B,D) for 24 h. Histogram shows the mean \pm SD (N=4) relative luciferase activity normalized to total protein levels in each sample.

While we have not performed paxillin ablation experiments using anti-sense paxillin RNA to determine whether paxillin is an essential coactivator in prostate cancer cells, we have observed efficient AR transactivation in cultured embryonic fibroblasts derived from paxillin knock out mice (data not shown). This suggests that paxillin is not an essential coactivator for AR, at least in embryonic fibroblasts. None of the experiments involving Her-2/neu effects on AR and paxillin have been performed as of yet.

In order to assess whether paxillin effects on AR and GR are direct, we used a GST pull-down assay to examine paxillin interactions with these receptors, as outlined in Specific Aim 2 (Task 2). We found that full-length paxillin-GST fusion protein bound to AR or GR expressed in transfected CV-1 cells or the GrH2 rat hepatoma cell line, respectively (Fig. 4). Control pull-down assays with GST alone did not result in the recovery of GR or AR while the focal adhesion kinase (FAK) protein was recovered with GST-paxillin pull-downs, as expected (Fig. 4). Importantly, the *in vitro* interaction between the steroid receptors (i.e. AR and GR) and paxillin was equally efficient when receptors were unliganded or hormone bound (data not shown). Furthermore, the interaction between the steroid receptors (i.e. AR and GR) and paxillin occurred through its carboxyl-terminal LIM domain. This result is consistent with previous domain mapping of Hic-5/ARA55, which delineated its carboxyl-terminal LIM domain region as a steroid receptor-interaction domain (14). Domains on AR that interact with paxillin remain to be established. In addition, studies to address the interaction of paxillin with DNA-bound AR remain to be performed.




Fig. 4. Hormone-independent interaction of paxillin with steroid receptors *in vitro*. Cell lysates of CV-1 cells transfected with human AR or the GRH2 hepatoma cell line were prepared after either a 2 h hormone treatment or non-treatment and incubated with a glutathione-sepharose-bound GST-FL-paxillin (A, B, C, and D), -NT-paxillin (C and D), or -CT-paxillin (C and D) fusion protein or GST protein for 3 h. Proteins eluted from glutathione-sepharose were subjected to Western blot analysis with anti-AR antibody (A and C) or anti-GR antibody (B and D) followed by reprobing with anti-FAK antibody (A and B).

Key Research Accomplishments

Task 1:

1. Identification of paxillin as a coactivator for androgen receptor in prostate cancer cell lines
2. Identification of paxillin domain required for androgen receptor coactivation
3. Demonstration that paxillin is not an essential coactivator for androgen receptor in embryonic fibroblasts

Task 2:

4. Demonstration of a direct interaction between androgen receptor and paxillin *in vitro*
5. Identification of paxillin domain that interacts with androgen receptor

Reportable Outcomes

- **Manuscripts**
- Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, Getzenberg RH, and DeFranco DB. The group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Research, *submitted* (3/03).

Conclusions

In this report we establish that paxillin, the founding member of group 3 LIM domain family, can be localized within the nucleus and in particular possesses nuclear matrix binding activity. In addition, we also show that paxillin can act as a coactivator for AR in fibroblasts and prostate cancer cell lines. Thus, paxillin and Hic-5/ARA55 have the capacity to function both at

focal adhesions to aid in the cell's interpretation of signals emanating from the ECM and within the nucleus to potentiate the transactivation activity of AR. It is well established that cellular proliferation and migration is very sensitive to signals that derive from the unique ECM composition of individual tissues. Such ECM-directed signals are thought to have a critical role in the progression of cells to a metastatic state. Our results implicate particular candidate proteins (i.e. group 3 LIM domain proteins) that may serve as direct transducers of ECM signals to the nucleus. Future work as outlined in the proposal will be directed towards establishing a link between plasma membrane and nuclear functions of paxillin and Hic-5/ARA55. If indeed these proteins act as coactivators that respond selectively to ECM signals, they could serve as potential highly specific therapeutic targets that seek to ablate AR responses to the ECM and reduce the metastatic potential of prostate cancer cells.

References

1. Mooradian, A.D., Morley, J.E., and Korenman, S.G. Biological actions of androgens. *Endocr. Rev.*, 8: 1-28, 1987.
2. Jenster, G. The Role of androgen receptor in the development and progression of prostate cancer. *Sem. Oncol.*, 26: 407-421, 1999.

3. Bourguet, W., Germain, P., and Gronemeyer, H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. *Trends Pharmacol. Sci.*, 21: 381-388, 2000.
4. Mangelsdorf, D.J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. The nuclear receptor superfamily: the second decade. *Cell*, 83: 835-839, 1995.
5. Cude, K.J., Dixon, S.C., Guo, Y., Lisella, J., and Figg, W.D. The androgen receptor: genetic considerations in the development and treatment of prostate cancer. *J. Mol. Med.*, 77: 419-426, 1999.
6. Keller, E.T., Ershler, W.B., and Chang, C. The androgen receptor: A mediator of diverse responses. *Front. Biosci.*, 1: d59-d71, 1996.
7. Slagsvold, T., Kraus, I., Fronsdal, K., and Saatcioglu, F. DNA binding-independent transcriptional activation by the androgen receptor through triggering of coactivators. *J. Biol. Chem.*, 276: 31030-31036, 2001.
8. Glass, C.K., and Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. *Genes Devel.*, 14: 121-141, 1999.
9. Kang, H.Y., Yeh, S., Fujimoto, N., and Chang, C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. *J. Biol. Chem.*, 274: 8570-8576, 1999.
10. Lee, D.K., Duan, H.O., and Chang, C. From androgen receptor to the general transcription factor TFIIF. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator. *J. Biol. Chem.*, 275: 9308-9313, 2000.

11. Park, J.J., Irvine, R.A., Buchanan, G., Koh, S.S., Park, J.M., Tilley, W.D., Stallcup, M.R., Press, M.F., and Coetzee, G.A. Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor. *Cancer Res.*, 60: 5946-5949, 2000.
12. Yang, F., Li, X., Sharma, M., Sasaki, C.Y., Longo, D.L., Lim, B., and Sun, Z. Linking beta-catenin to androgen signaling pathway. *J. Biol. Chem.*, 277: 11336 – 11344, 2002.
13. Fujimoto, N., Yeh, S., Kang, H.Y., Inui, S., Chang, H.C., Mizokami, A., and Chang, C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. *J. Biol. Chem.*, 274: 8316-8321, 1999.
14. Yang, L., Guerrero, J., Hong, H., DeFranco, D.B., and Stallcup, M.R. Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. *Mol. Biol. Cell*, 11: 2007-2018, 2000.
15. Matsuya, M., Sasaki, H., Aoto, H., Mitaka, T., Nagura, K., Ohba, T., Ishino, M., Takahashi, S., Suzuki, R., and Sasaki, T. Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. *J. Biol. Chem.*, 273: 1003-1014, 1998.
16. Thomas, S.M., Hagel, M., and Turner, C.E. Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin. *J. Cell Sci.*, 112: 181-190, 1999.
17. Schaller, M.D. Paxillin: a focal adhesion-associated adaptor protein. *Oncogene*, 20: 6459-6472, 2001.
18. Turner, C.E. Paxillin and focal adhesion signaling. *Nat. Cell Biol.*, 2: E231-E216, 2000.

19. Perez-Alvarado, G.C., Miles, C., Michelsen, J.W., Louis, H.A., Winge, D.R., Beckerle, M.C., and Summers, M.F. Structure of the carboxy-terminal LIM domain from the cysteine rich protein CRP. *Nat. Struct. Biol.*, *1*: 388-398, 1994.
20. Nix, D.A., and Beckerle, M.C. Nuclear-cytoplasmic shuttling of focal contact protein, zyxin: A potential mechanism for communication between sites of cell adhesion and the nucleus. *J. Cell Biol.*, *138*: 1139-1147, 1997.